"10.1371_journal.pone.0152720","plos one","2016-04-07T00:00:00Z","Benjamine Arellano; Rehana Hussain; William A Miller-Little; Emily Herndon; Doris Lambracht-Washington; Todd N Eagar; Robert Lewis; Don Healey; Steven Vernino; Benjamin M Greenberg; Olaf Stüve","Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, United States of America; Department of Pathology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, United States of America; Histocompatibility and Transplant Immunology, Department of Pathology and Genomic Medicine, The Methodist Hospital Physician Organization, Houston, TX, United States of America; Opexa Therapeutics, The Woodlands, TX, United States of America; Neurology Section, VA North Texas Health Care System, Medical Service, Dallas, TX, United States of America; Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany","Conceived and designed the experiments: BA RH WM EH DL TE RL SV BG OS. Performed the experiments: BA RH WM EH DL TE RL OS. Analyzed the data: BA RH WM EH DL DH SV BG OS. Contributed reagents/materials/analysis tools: TE SV OS. Wrote the paper: BA RH WM EH DL TE RL DH SV BG OS.","Dr. Olaf Stuve serves on the editorial boards of JAMA Neurology, Multiple Sclerosis Journal, and Therapeutic Advances in Neurological Disorders. Dr. Stüve has served on data monitoring committees for Pfizer and Sanofi-Aventis without monetary compensation. Dr. Stüve collaborated with Medscape on educational initiatives. Dr. Stüve represented Novartis in front of a Scientific Advisory Group at the European Medicines Agency (EMA). Dr. Stüve has advised Genentech and Sanofi-Aventis. Dr. Stüve has consulted for Huron Life Sciences and Navigant Consulting. Dr. Stüve currently receives grant support from Teva Pharmaceuticals and Opexa Therapeutics. Dr. Stüve received travel support from Pfizer. Dr. Stüve is funded by a Merit grant from the US Department of Veterans Affairs. Dr. Healey is an employee of Opexa Therapeutics. These commercial affiliations do not alter the authors adherence to PLOS ONE policies on sharing data and materials.","2016","04","Benjamine Arellano","BA",11,TRUE,10,8,9,11,TRUE,TRUE,FALSE,0,NA,FALSE
